Search results for: “Crispr”
-
Start-Up Adapts Crispr for Molecular Detection, Raises $40M
A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler.
-
One-Time Crispr HIV Therapy Given Fast-Track Status
A treatment for HIV taken just once, using the genome-editing technology Crispr, is receiving fast-track designation from the U.S. Food and Drug Administration.
-
Crispr Therapy Shown to Reduce Harmful Gut Microbes
A clinical trial shows an oral therapy with engineered viruses delivers precise gene-edited payloads to reduce E. coli communities in the gut with no serious adverse effects.
-
Crispr Therapy Shown to Remove E. Coli in Gut
New research with lab animals shows gene-edited viruses can target and remove harmful E. coli bacteria from the gut, including strains usually resistant to antibiotics.
-
Patent Issued for Crispr-Edited Viruses in Microbiome
A biotechnology company developing gene-edited therapies for bacterial infections in the gut received a U.S. patent for viruses engineered as treatments.
-
Patent Issued for Anti-Bacterial Viruses with Crispr Payloads
A biotechnology company received a patent for its engineered viruses to deliver gene-edited treatments to combat bacterial infections in the microbiome.
-
Early Trial Data Show Crispr Cancer Therapy Response
Initial results from a clinical trial show non-Hodgkin lymphoma patients receiving low doses of gene-edited T-cells achieve a clinical response, but with some adverse effects.
-
Trial Begins Testing Crispr Gut Microbiome Therapy
A clinical trial is underway assessing a genetically edited oral drug designed to remove E. coli in the gut, a danger for patients with blood-related cancers.
-
Patent Board Rules for Broad Inst. in Crispr Case
A U.S. patent appeals board ruled that the Broad Institute at Harvard and MIT is the discoverer of Crispr gene editing techniques in animal cells.
-
Clinical Trial Underway for One-Time Crispr HIV Treatment
A clinical trial is underway assessing a therapy for HIV infections that aims to eradicate the virus with one dose of the gene-editing technique Crispr.